Open AccessClinical guidelines for cryosupernatant transfusions
Author(s) -
Г М Галстян,
Т. В. Гапонова,
Ф. С. Шерстнев,
А.А. Купряшов,
Н. И. Оловникова,
Н. И. Зозуля,
В В Троицкая,
В.А. Мазурок,
Д. Э. Певцов,
Э. Л. Салимов,
Pavel Trakhtman,
В Г Савченко
Publication year - 2020
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2020-65-3-351-359
Subject(s) - cryoprecipitate , fresh frozen plasma , medicine , von willebrand factor , antithrombin , thrombotic thrombocytopenic purpura , fibrinogen , platelet , heparin
. Cryosupernatant is blood component. Cryosupernatant is the supernatant plasma removed during the preparation of cryoprecipitate. Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of Cryosupernatant. General fi ndings. In comparison with fresh frozen plasma (FFP) and cryoprecipitate, Cryosupernatant plasma is depleted in factor VIII, fi brinogen factor von Willebrand (VWF). Cryosupernatant is defi cient in high molecular weight multimers of VWF, but contains VWF metalloproteinase. The concentrations of factor V, antithrombin III, albumin and immunoglobulins are the same as in FFP and cryoprecipitate. The indications for Cryosupernatant transfusions are massive blood loss in patients with factor VIII inhibitor, plasma exchange in patients with thrombotic thrombocytopenic purpura. For children the doses of Cryosupernatant should be 10-15 mL/kg.